

**CURRICULUM VITAE**

**Name:** Gerard Sanacora, M.D., Ph.D.  
**School:** Yale University School of Medicine  
**Education:** B.S. State University of New York (SUNY) at Stony Brook, Stony Brook, NY, 1986  
M.D. SUNY at Stony Brook, Stony Brook, NY, 1994  
Ph.D. SUNY at Stony Brook, Stony Brook, NY; Physiology and Biophysics, 1992

**Current Academic Appointment:**

2010-present Professor, Dept. of Psychiatry, Yale University School of Medicine, New Haven, CT

**Major Professional Honors & Recognition**

- 2011 Recipient of the Joel Elkes Research Award for outstanding contributions to Psychopharmacology from the American College of Neuropsychopharmacology
- 2009 Recipient of the ANNA-MONIKA-FOUNDATION Award for the investigation of the biological substrate and functional disturbances of depression
- 1999: Recipient of Charles A. Dana Foundation Award for Clinical Hypotheses in Neuroscience

**BIBLIOGRAPHY:**

- Sanacora, G.**, Gueorguieva, R., Epperson, C.N., Wu, Y.T., Appel, M., Rothman, D.L., Krystal, J.H., Mason, G.F. Subtype-specific alterations of GABA and glutamate in major depression. *Archives of General Psychiatry*. 2004, 61(7): 705-713.
- Ostroff, R., Gonzales, M., **Sanacora, G.** Antidepressant effect of ketamine during ECT. *Am J Psychiatry*. 2005, 162(7):1385-6.
- Mineur, Y.S., Picciotto, M.R., **Sanacora, G.** Antidepressant-like effects of ceftriaxone in male C57BL/6J mice, *Biological Psychiatry*. 2006, 61(1), 250-2
- Sanacora, G.**, Kendell, S., Levin, Y., Simen, A.A., Fenton, L.R., Coric, V., Krystal, J.H. Preliminary evidence of riluzole efficacy in antidepressant-treated patients residual depression symptoms. *Biological Psychiatry*. 2007, 61(6):822-825.
- Banasr, M., Chowdhury, G.M.I., Twillenger, R., Newton S., Duman, R.S., Behar K., **Sanacora, G.** Stress-induced glial pathology and depressive-behaviors are prevented by riluzole. *Molecular Psychiatry. Mol Psychiatry*. 2010 May;15(5):501-11.
- Sanacora, G.**, Zarate, C. Krystal, J. Manji, H. Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. *Nature Reviews Drug Discovery*. 2008, 7(5):426-37. Valentine G, Mason GF, Gomez R, Fasula M, Watzl J, Pittman B, Krystal JH,
- Sanacora G.** The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [1H]-MRS. *Psychiatry Research: Neuroimaging* 2011 Feb 28;191(2):122-7
- Popoli M, Yan Z, McEwen BE, **Sanacora G**, The Stressed Synapse: The Impact of Stress and Glucocorticoids on Glutamate Transmission, *Nature Reviews Neuroscience*, 2011 Nov 30;13(1):22-37.
- Chowdhury GM, Behar KL, Cho W, Thomas MA, Rothman DL, **Sanacora G.** (1)H-[(13)C]-Nuclear Magnetic Resonance Spectroscopy Measures of Ketamine's Effect on Amino Acid Neurotransmitter Metabolism. *Biol Psychiatry*, 2012 Jun 1;71(11):1022-5.
- Sanacora G**, Duman RS. The revolution in rapid-acting antidepressants. *Biol Psychiatry*. 2013 Jun 15;73(12):1123-4.
- Sanacora G**, Banasr M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders *Biol Psychiatry*. 2013 Jun 15;73(12):1172-9.
- Sanacora, G.**, Smith, M., Pathak, S., Su H., Boeijinga, P., McCarthy, D., Quirk, M. AZD6765: A lowtrapping NMDA channel blocker produces sustained antidepressant efficacy with minimal psychotomimetic adverse effects. *Molecular Psychiatry*. [In Press]